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Abstract: CDK2/cyclin A has appeared as an attractive drug targets over the years with 
diverse  therapeutic  potentials.  A  computational  strategy  based  on  comparative  
molecular  fields  analysis  (CoMFA)  and  comparative  molecular  similarity  indices  
analysis (CoMSIA) followed by molecular docking studies were performed on a series of  
4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline  derivatives  as  potent  CDK2/cyclin  A 
inhibitors. The CoMFA and CoMSIA models, using 38 molecules in the training set, gave 
r
2
cv values of 0.747 and 0.518 and r
2 values of 0.970 and 0.934, respectively. 3D contour 
maps  generated  by  the  CoMFA  and  CoMSIA  models  were  used  to  identify  the  key 
structural  requirements  responsible  for  the  biological  activity.  Molecular  docking  was 
applied to explore the binding mode between the ligands and the receptor. The information 
obtained from molecular modeling studies may be helpful to design novel inhibitors of 
CDK2/cyclin A with desired activity. 
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1. Introduction 
Essentially  all  physiological  processes  and  a  majority  of  human  diseases  involve  protein 
phosphorylation. Given the fact that protein phosphorylation is a primary post-translational mechanism 
applied  by  cells  to  regulate  enzymes  and  other  proteins  in  each  of  the  cell  cycle  transitions,  its 
deregulation has been regarded as the cause or consequence of many maladies [1–3]. CDKs/cyclins,  
a  series  of  binary  protein  kinase,  show  genetic  defects  in  many  malignant  diseases  such  as  
Alzheimer’s [4], Parkinson’s [5], Nieman-Pick’s diseases [6], and ischemia [7] as well as traumatic 
brain injury [8], when deregulated. CDKs/cyclins exert their effects via activation of host proteins 
through phosphorylation of key serine or threonine residues by  ATP.  It  was  revealed in  previous 
studies  that  the  inhibitors  of  these  CDKs/cyclins  were  down-regulated  in  most  of  the  cancer  
cells [9,10]. A considerable amount of investigations have been carried out to develop inhibitors that 
target CDK2/cyclin A for treating  cancer, and several CDK2/cyclin A inhibitors have been under 
clinical evaluation [10]. 3D-QSAR and docking approaches have emerged as one of the most powerful 
tools in ligand based drug design strategies [11,12]. They have been used to develop efficient models 
for identifying CDK2/cyclin A inhibitors [13,14]. 
Recently, a series of compounds containing 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline that have 
potent CDK2/cyclin A inhibitory activities were reported by literature [15]. In this paper, molecular 
modeling studies of these 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives were performed by 
using 3D-QSAR and docking approaches. 3D-QSAR including comparative molecular field analysis 
(CoMFA) and comparative molecular similarity indices analysis (CoMSIA) methods were performed 
to  predict  the  inhibitory  activities  of  these  inhibitors,  and  to  provide  the  regions  in  space  where 
interactive fields may influence the activity. Meanwhile, a docking study was employed to investigate 
the  protein-ligand  interactions.  The  constructed  models  can  help  not  only  in  understanding  the 
structure-activity relationship of these compounds but can also serve as a useful guide for the design of 
new inhibitors with desired potencies. 
2. Results and Discussion 
2.1. CoMFA Model 
The statistical parameters corresponding to the CoMFA model are listed in Table 1. The CoMFA 
model  of  a  series  of  4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline  derivatives  was  generated  using  
leave-one-out  PLS  analysis  with  an  optimized  component  of  5  to  give  a  good  cross-validated 
correlation coefficient (r
2
cv) of 0.747 (>0.5), which suggesting that the model should be a reasonable 
tool for predicting the IC50 values. A high non-cross-validated correlation coefficient (r
2) of 0.970 with 
a low standard error estimate (SEE) of 0.225 was obtained as well as an F value of 206.080 and 
predictive correlation coefficient (r
2
pred) of 0.942. Contributions of steric and electrostatic fields were 
0.599 and 0.401, respectively. The actual and predicted pIC50 values of the training set and test set by 
the model are listed in Table 2, and the graph of actual activity versus predicted pIC50 of the training 
set and test set is illustrated in Figure 1. Int. J. Mol. Sci. 2010, 11                       
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Table 1. Results of CoMFA and CoMSIA Models. 
PLS Statistics  CoMFA  CoMSIA 
r
2
cv 
a  0.747  0.518 
r
2 b  0.970  0.934 
ONC 
c  5  6 
SEE 
d  0.225  0.339 
F value 
e  206.080  72.528 
r
2
pred 
f  0.942  0.931 
Field contribution     
Steric  0.599  0.373 
Electrostatic  0.401  0.472 
Hydrophobic  -  - 
H-bond Donor  -  - 
H-bond Acceptor  -  0.155 
a  cross-validated  correlation  coefficient; 
b  non-cros-validated  coefficient; 
c  optimal  number  of 
components; 
d standard error of estimate; 
e value F-test value; 
f predictive correlation coefficient. 
Figure 1. Graph of actual versus predicted pIC50 values of the training set and the test set 
molecules using the CoMFA model. 
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Table  2.  The  actual  pIC50s,  predicted  pIC50s  (Pred.)  and  their  residuals  (Res.)  of  the 
training and test set molecules. 
Compd.  pIC50  CoMFA  CoMSIA 
No.  Actual  Pred.  Res.  Pred.  Res. 
1*  8.699  8.402  0.297  8.405  0.294 
2  8.301  8.166  0.135  8.535  −0.234 
3*  7.824  7.629  0.195  7.555  0.269 
4  8.699  8.613  0.086  8.534  0.165 
5  8.155  7.547  0.608  7.440  0.715 
6  7.337  7.727  −0.390  7.943  −0.606 
7  6.983  6.942  0.041  7.101  −0.118 
8*  7.523  7.402  0.121  7.315  0.208 
9  6.600  6.602  −0.002  6.854  −0.254 
10  8.523  8.701  −0.178  8.615  −0.092 
11  7.721  7.778  −0.057  7.581  0.140 
12  7.092  6.704  0.388  6.720  0.372 
13  5.409  5.750  −0.341  5.658  −0.249 
14  6.241  6.219  0.022  6.183  0.058 
15  6.514  6.466  0.048  6.684  −0.170 
16  8.222  8.115  0.107  8.210  0.012 
17*  8.523  8.994  −0.471  8.428  0.095 
18  5.899  5.887  0.012  5.851  0.048 
19  8.699  8.788  −0.089  8.774  −0.075 
20*  8.699  8.676  0.023  8.819  −0.120 
21  7.387  7.485  −0.098  7.345  0.042 
22  8.301  8.521  −0.220  8.275  0.026 
23  8.398  8.360  0.038  8.424  −0.026 
24*  6.680  7.088  −0.408  6.063  0.617 
25  8.301  8.194  0.107  8.310  −0.009 
26*  7.854  8.137  −0.283  8.305  −0.451 
27  8.523  8.324  0.199  8.185  0.338 
28  6.848  7.253  −0.405  7.573  −0.725 
29  7.770  8.037  −0.267  7.844  −0.074 
30  8.155  8.136  0.019  7.719  0.436 
31  6.446  6.455  −0.009  6.656  −0.210 
32*  5.839  5.837  0.002  5.429  0.410 
33  5.561  5.430  0.131  5.515  0.046 
34  5.951  6.011  −0.060  5.844  0.107 
35  5.871  5.920  −0.049  5.754  0.117 
36  5.721  5.564  0.157  5.532  0.189 
37  6.243  5.598  0.645  6.139  0.104 
38  6.355  6.220  0.135  5.995  0.360 
39  5.000  5.018  −0.018  4.846  0.154 
40  5.000  5.439  −0.439  5.833  −0.833 
41  8.155  8.019  0.136  7.869  0.286 
42  5.984  5.849  0.135  5.709  0.275 
43*  5.950  5.443  0.507  5.979  −0.029 
44  5.000  4.940  0.060  5.326  −0.326 
45  5.000  5.053  −0.053  5.040  −0.040 
46  7.086  7.019  0.067  6.823  0.263 
47  6.450  6.583  −0.133  6.456  −0.006 
* Test Set Molecules. Int. J. Mol. Sci. 2010, 11                       
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2.2. CoMSIA Model 
The statistical parameters corresponding to the CoMSIA model are listed in Table 1. The CoMSIA 
model,  consisting  of  steric  (S),  electrostatic  (E),  hydrophobic  (H),  hydrogen  bond  donor  (D)  and 
acceptor  (A)  fields,  can  be  generated  using  these  fields  in  different  combinations.  The  results  of 
CoMSIA analysis with different combinations are summarized in Table 3. Among the combination 
models, steric, electrostatic and hydrogen bond acceptor fields played essential roles for the present 
series of compounds. To confirm whether the addition of hydrophobic, hydrogen bond donor and 
acceptor fields affect the model, each descriptor was considered along with steric and electrostatic 
descriptors for generating the model. Inclusion of the hydrophobic field descriptor caused a reduction 
in both r
2
cv and r
2
pred, which implied that the hydrophobic field descriptor may not be crucial for these 
molecules. Moreover, the removal  of steric  and electrostatic descriptors (H  + D  + A) resulted in 
significant  reduction  in  r
2
cv,  r
2  and  r
2
pred.  The  S  +  E  +  A  combination  was  better  than  the  
S  +  E  +  H  +  D  +  A  combination  in  every  statistical  parameter,  which  suggested  that  the  steric, 
electrostatic  and  hydrogen  bond  acceptor  functional  groups  were  of  extreme  significance  for  the 
inhibitory activity. In conclusion, the combination of steric, electrostatic and hydrogen bond acceptor 
fields was selected as the best model.  
Table 3. Summary of CoMSIA Analysis. 
  r
2
cv  r
2  ONC  SEE  F value  r
2
pred 
S + E  0.593  0.943  6  0.315  85.009  0.965 
S + E + H  0.415  0.947  6  0.303  92.344  0.887 
S + E + D  0.449  0.940  6  0.322  80.894  0.937 
S + E + A*  0.518  0.934  6  0.339  72.528  0.931 
H + D + A  0.276  0.637  2  0.746  30.677  0.555 
S + E + H + D  0.337  0.953  6  0.287  103.677  0.848 
S + E + H + A  0.397  0.944  6  0.311  87.122  0.843 
S + E + D + A  0.422  0.892  4  0.419  68.166  0.843 
S + E + H + D + A  0.355  0.944  6  0.310  87.636  0.769 
S: Steric; E: Electrostatic; H: Hydrophobic; D: H-bond Donor; A: H-bond Acceptor; * Best model 
for CoMSIA. 
The CoMSIA model with a combination of steric, electrostatic and hydrogen acceptor fields gave a 
good cross-validated correlation coefficient (r
2
cv) of 0.518 (>0.5) with an optimized component of 6. A 
high non-cross-validated correlation coefficient (r
2) of 0.934 was attained, as well as a low standard 
error estimate (SEE) of 0.339, F value of 72.528 and predictive correlation coefficient (r
2
pred) of 0.931. 
Contributions of steric, electrostatic and hydrogen bond acceptor fields were 0.373, 0.472 and 0.155, 
respectively. The actual and predicted pIC50 values and residual values for the training set and test set 
compounds are listed in Table 2. The association between actual and predicted pIC50 of the training set 
and test set compounds is illustrated in Figure 2. 
 Int. J. Mol. Sci. 2010, 11                       
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Figure 2. Graph of actual versus predicted pIC50 values of the training set and the test set 
molecules using the CoMSIA model. 
4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5
8.0
8.5
9.0
 Training Set
 Test Set
P
r
e
d
i
c
t
e
d
 
p
I
C
5
0
 
b
y
 
C
o
M
S
I
A
Actual pIC
50  
2.3. CoMFA Contour Maps 
To view the information of the resultant 3D-QSAR model, CoMFA contour maps were generated to 
rationalize the regions in 3D space around the molecules where changes in the steric and electrostatic 
fields  were  predicted  to  enhance  or  lessen  the  activity  of  the  compound.  The  CoMFA  steric  and 
electrostatic contour maps are shown in Figure 3. 
The steric field is characterized by green and yellow contours, in which yellow contours indicate 
regions where minor groups would be favorable, while the green contours represent regions where 
minor groups would decrease the activity. Compound 19 was selected as a reference structure. As 
shown in Figure 3A, the N-1 position (R1) was surrounded by two small yellow contours, which 
suggested a minor group at this position would increase the inhibitory potency. This may explain why 
compounds  01,  02,  04  which  possessed  a  minor  group  (e.g.,  Me,  H)  at  R1  showed  significantly 
increased activities compared to those with a bulky substituent. For instance, compounds 1–8 had an 
order for the potency of 01 > 02 > 05 > 03 > 08 > 07, with the corresponding R1 substituent Me, 
F3CCH2-,  Cyclohexane,  Phenyl,  1-piperidine-CH2-CH2-,  1-methyl-piperidine-,  respectively.  The 
presence of the yellow contour around the C-3 (R2) position also suggested a bulky group at this region 
would be unfavorable. By checking up all the C-3 modified compounds, it was found that derivatives 1 
and 9–14 have the activity order of 1 (R2 = NH2) > 10 (R2 = OH) > 11 (R2 = NHMe) > 9 (R2 = OEt) > 
12  (R2 =  NHcyclopropyl)  >  13  (R2 =  NHcyclopentyl)  >  14  (R2 =  NHPh).  This  is  satisfactory  in 
accordance with the contour map. The large yellow contour around the benzene at R3 indicated that 
minor groups at this position may benefit potency. This may explain why compound 28 (R3 = SMe) 
was more potential than 34 (R3 = SO2NH2), while compound 34 (R3 = SO2NH2) was more active  
than 40 (R3 = SPh). Comparing compound 27 (R3 = Me) with 31 (R3 = i-Pr), as well as 18 (R3 = Ac)  Int. J. Mol. Sci. 2010, 11                       
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with 32 (R7 = CO2Me), it could be easily found that their activity discrepancies can also be explained 
by this yellow contour.  
Figure  3.  Std*  coeff  contour  maps  of  CoMFA  analysis  with  2  Å  grid  spacing  in 
combination with compound 19: (A) Steric fields: green contours indicate regions where 
bulky  groups  increase  activity;  yellow  contours  indicate  regions  where  bulky  groups 
decrease activity, and (B) Electrostatic fields: blue contours (80% contribution) represent 
regions where electron-donating groups increase activity; red contours (20% contribution) 
represent regions where electron-withdrawing groups increase activity. 
 
(A) 
 
(B) 
The electrostatic field (Figure 3B) is indicated by blue and red contours, which exhibit the regions 
where electron-donating groups and electron-withdrawing groups would be favorable, respectively. 
Compound 19 was selected as a reference molecule again. In the CoMFA electrostatic field, a strip 
blue  contour  around  the  N-1  (R1)  side  chain  revealed  the  electron-donating  substituent  was  
essential for the inhibitory activity. Take the compound 2 (R1 = CF3CH2) for an example: The strong  
electron-withdrawing  -CF3  group  at  the  terminal  of  N-1  side  chain  in  compound  2  resulted  in 
significantly  decreased  activity  compared  to  the  compound  1  with  the  electron-donating  Int. J. Mol. Sci. 2010, 11                       
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substituent  -CH3.  The  red  contour  near  the  C-3  (R2)  position  demonstrated  that  the  electron-
withdrawing groups at this position would benefit potency, this may be the reason why compounds 9, 
and  11–13,  which  possessed  electron-donating  groups,  had  decreased  potencies  compared  to  the 
compounds with -OH group such as compound 10 (R2 = OH). The three red contours around the 
benzene at R3 revealed that the electron-withdrawing groups at this position may increase the potency. 
For  instance,  compounds  30,  29,  31  had  an  order  for  the  activity  of  30  >  29  >  31,  with  the 
corresponding R3 substituent -F, -NHMe, i-Pr, respectively.  
2.4. CoMSIA Contour Maps 
The best combination model for CoMSIA were steric, electrostatic and hydrogen bond acceptor 
fields (Table 3). The hydrophobic and hydrogen bond donor fields were not essential for the CoMSIA 
model, thus their contours were not generated. The CoMSIA steric and electrostatic field contour maps 
were approximately similar to the corresponding CoMFA contour maps, therefore the figures were not 
illustrated, either (Figure 4A or 4B). 
The  hydrogen  bond  acceptor  field  contour  map  of  CoMSIA  is  shown  in  Figure  4  using  
compound  19  as  a  reference  molecule.  The  magenta  and  red  contours  represent  favorable  and 
unfavorable  hydrogen  bond  acceptor  groups.  In  the  CoMSIA  hydrogen  bond  fields,  the  magenta 
contour  near  the  benzene  (m,p-R3)  revealed  that  hydrogen  bond  acceptor  groups  may  benefit  the 
potency. The -F, -O, and -N atom at this position acted as hydrogen bond acceptor, this may explain 
why compounds 16–17, 19–20, 22–23 and 25–26 showed relatively better activities. One huge red 
contour  around  the  benzene  (o-R3)  revealed  that  hydrogen  bond  acceptor  groups  may  decrease  
the  inhibitory  activity.  For  example,  compounds  1,  15,  29,  30  had  an  order  for  the  activity  of  
1 > 30 > 29 > 15, with the corresponding o-R3 substituent -H, -F, -NHMe, -CF3, respectively. 
2.5. Docking Analysis 
Docking was implemented to find the probable binding conformations between these 4,5-dihydro-
1H-pyrazolo[4,3-h]quinazoline derivatives and the receptor, furthermore, to check the reliability of the 
3D-QSAR models established. Since the crystal structure of CDK2/cyclin A was known, we docked 
compound 19 into the allosteric site of CDK2/cyclin A (PDB code 2WXV), and the surfex-dock total 
score was 9.17.  
As shown in Figure 5, the key residues and hydrogen bonds were labeled, namely: the O and N at 
the C-3 position of the pyrazolo ring in compound 19 served as hydrogen bond acceptor and donor by 
forming two H-bond with the -NH2, -OH group of LEU83 residue, respectively. The N atom of the 
pyrimidine ring and the O atom of m-Ac in compound 19 acted as the hydrogen bond acceptors by 
forming two H-bonds with -NH2 group of LYS33 residue. The results confirmed the observation from 
the CoMSIA hydrogen bond acceptor contour map. 
 Int. J. Mol. Sci. 2010, 11                       
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Figure  4.  Std*  coeff  contour  maps  of  CoMSIA  analysis  with  2  Å  grid  spacing  in 
combination  with  compound  19:  (A)  Steric  fields:  Green  contours  (80%  contribution) 
indicate regions where bulky groups increase activity; yellow contours (20% contribution) 
indicate  regions  where  bulky  groups  decrease  activity;  (B)  Electrostatic  fields:  Blue 
contours  (80%  contribution)  represent  regions  where  electron-donating  groups  increase 
activity;  red contours  (20% contribution) represent  regions  where  electron-withdrawing 
groups increase activity; (C) hydrogen bond acceptor contour map. The magenta and red 
(80% and 20% contributions) contours indicate favorable and unfavorable hydrogen bond 
acceptor groups. 
 
(A) 
 
(B) 
 
(C) 
In order to test and verify the use of docking, the MOLCAD surface with cavity depth potential was 
generated and is shown in Figure 6. The cavity depth measures how deep a surface point is located 
inside  a  cavity  of  a  molecule.  The  cavity  depth  color  ramp  ranges  from  blue  (low  depth  values 
represent outside of the molecule) to light red (high depth values represent cavities deep inside the 
molecule). It can be observed that the whole molecule was in the light red region (Figure 6) which 
revealed that compound 19 was placed well in the allosteric site.  Int. J. Mol. Sci. 2010, 11                       
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Figure  5.  The  binding  mode  between  compound  19  and  the  allosteric  site  of  
CDK2/cyclin A (PDB code 2WXV). Key residues and hydrogen bonds are labeled. 
 
Figure 6. MOLCAD cavity depth potential surface of the allosteric site of CDK2/cyclin A 
(PDB code 2WXV) within the compound 19. Light red color denotes the deepest depth. 
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The  MOLCAD  surface  of  the  allosteric  site  was  developed  and  displayed  with  electrostatic 
potential  to  test  and  verify  the  CoMFA  electrostatic  contour  map  (Figure  7).  The  molecular 
electrostatic potential on a protein surface can be applied to find the sites that act attractively on 
ligands by matching opposite colors. The compound 19 was docked into the allosteric site; the red 
color  shows  the  electron-withdrawing  zone  and  purple  color  shows  electron-donating  zone.  The 
observation seen in Figure 7 was satisfactory according to that of CoMFA electrostatic contour map. In 
detail, the R2 region is in the red zone, which suggested that electron-withdrawing substituent would be 
favorable;  the  R1  region  is  in  a  blue  zone,  which  indicated  that  electron-donating  groups  may  
be favorable. 
To better visualize the protein structure, in this paper, protein residues were explored using the 
ribbon program (Figure 8). The protein backbone is drawn as a ribbon or tube. Representations of 
proteins in Richardson style use arrows for beta strands, cylinders for alpha helices and tubes for coils 
and turns. As showed in Figure 8, the two protein residues involved—LYS33 and LEU83—lie within 
arrows designating beta strands. 
Figure  7.  The  MOLCAD  electrostatic  potential  surface  of  the  allosteric  site  of 
CDK2/cyclin  A  (PDB  code  2WXV)  within  the  compound  19.  The  color  ramp  for  EP 
(electrostatic potential) ranges from red (most positive) to purple (most negative). 
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Figure 8. The MOLCAD Ribbon Surfaces of the allosteric site of CDK2/cyclin A (PDB 
code 2WXV) within the compound 19. 
 
2.6. Design of New Molecules Based on COMFA, CoMSIA and Docking Studies 
The detailed contour map analysis of both COMFA and CoMSIA models and the docking analysis 
empowered  us  to  identify  structural  requirements  for  the  observed  inhibitory  activity  (Figure  9).  
The  molecules  were  modified  to  further  improve  the  inhibition  activity  toward  CDK2/CyclinA.  
Compound 19 were chosen as a reference structure to design new molecules to obtain a number of new 
potent molecules (Figure 10). The newly designed molecules were docked into the protein active site. 
The COMFA and CoMSIA models established above were used to predict the activity by applying the  
3D-QSAR model. The new molecules showed better dock score and predicted activity (Table 4). The 
comparison of the predicted activity of the newly designed molecules between CoMFA and CoMSIA 
models are showed in Figure 11. The designed molecules showed better activity than the reference 
molecules, which indicates that the 3D-QSAR model has a good predictability and can be used to 
design new molecules with better activity. 
Figure 9. Structural requirements for binding and inhibitory activity of inhibitors. 
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Figure 10. Structure of newly designed molecules. 
           R1                  R2                    R3                 R4
d1       H                   NH2                 Ac                  H
d2       H                   NH2                 H                    CF3
d3       H                   NH2                 H                    OEt
d4       H                   NH2                 H                    OMe
d5       H                   NH2                 H                    CONH2
d6       H                   OH                  Ac                    H
d7       H                   OH                  Ac                    Ac
d8       H                   NH2                Ac                    Ac
d9       H                   OMe               Ac                    Ac
d10     H                 NHMe              Ac                    Ac
d11     H                 NHNH2            Ac                    Ac
d12     H                   OH                  H                     Ac
d13     H                   OH                  H                 OC(CH3)3
d14     H                   OH                CONH2         CONH2
d15     H                   OH                  H                   CONH2
d16     H                   OH                  H                     OEt
d17     H                   OH                  H                     OCF3
N
N
N N
R2
O
R1
HN
R3
R4
 
Table 4. Surflex-Dock total-score and predicted activity of newly designed molecules. 
Compound 
Predicted pIC50 
Total-Score 
CoMFA  CoMSIA 
19  8.788  8.774  9.17 
d1  8.903  9.293  8.62 
d2  9.393  8.447  7.20 
d3  8.360  8.949  9.02 
d4  8.547  8.940  6.53 
d5  8.998  9.286  7.27 
d6  8.726  9.470  6.57 
d7  8.603  9.347  8.36 
d8  8.871  9.116  6.68 
d9  8.833  8.731  7.13 
d10  8.552  8.837  6.50 
d11  8.730  9.027  7.82 
d12  8.628  9.517  7.51 
d13  9.082  8.713  5.89 
d14  9.094  9.719  8.45 
d15  8.722  9.507  7.30 
d16  8.527  9.345  9.25 
d17  9.115  8.675  5.99 Int. J. Mol. Sci. 2010, 11                       
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Figure  11.  Graph  of  the  predicted  pIC50  of  the  newly  designed  molecules  versus  
compound 19. 
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3. Materials and Methods 
3.1. Data Sets 
The  47  compounds  involved  in  this  study  were  taken  from  the  literature  [15].  The  inhibitory 
activities were reported as IC50 against CDK2/cyclin A. The IC50 values were converted into pIC50 by 
taking Log (1/IC50). The entire derivatives were divided into a training set of 38 compounds and a test 
set  of  nine  compounds  for  model  validation.  The  test  set  compounds  were  selected  randomly. 
Chemical structures and associated inhibitory activities are shown in Table 5 and Table 1. 
Table 5. The Structures of the Training and Test Set Molecules. 
N
N
N N
HN
R1
R2
O
R4
R3
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Table 5. Cont. 
Compd.  
No. 
Substituent 
R1  R2  R3   R4 
1  Me  NH2  H  H 
2  F3C
 
NH2  H  H 
3 
 
NH2  H  H 
4  H  NH2  H  H 
5 
 
NH2  H  H 
6  i-Pr  NH2  H  H 
7  N Me
 
NH2  H  H 
8  N
 
NH2  H  H 
9  Me  OEt  H  H 
10  Me  OH  H  H 
11  Me  NHMe  H  H 
12  Me  NHcyclopropyl  H  H 
13  Me  NHcyclopentyl  H  H 
14  Me  NHPh  H  H 
15  Me  NH2  o-CF3  H 
16  Me  NH2  m-CF3  H 
17  Me  NH2  p-CF3  H 
18  Me  NH2  o-Ac  H 
19  Me  NH2  m-Ac  H 
20  Me  NH2  p-Ac  H 
21  Me  NH2  o-OMe  H 
22  Me  NH2  m-OMe  H 
23  Me  NH2  p-OMe  H 
24  Me  NH2  o-NO2  H 
25  Me  NH2  m-NO2  H 
26  Me  NH2  p-NO2  H 
27  Me  NH2  o-Me  H 
28  Me  NH2  o-SMe  H 
29  Me  NH2  o-NHMe  H 
30  Me  NH2  o-F  H 
31  Me  NH2  o- i-Pr  H 
32  Me  NH2  o-CO2Me  H 
33  Me  NH2  o-CONH2  Cl 
34  Me  NH2  o-SO2NH2  H 
35  Me  NH2  o-Ph  H 
36  Me  NH2  o-OPh  H 
37  Me  NH2  o-benzyl  H 
38  Me  NH2  o-NHPh  H 
39  Me  NH2  o-benzoyl  H 
40  Me  NH2  o-SPh  H 
41  Me  NH2  o-NH2  H Int. J. Mol. Sci. 2010, 11                       
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Table 5. Cont. 
42  Me  NH2  o-NHAc  H 
43  Me  NH2  o-Ac  3'-(4-methyl-piperazin-1-yl) 
44  Me  NH2  o-Ac  4'-(4-methyl-piperazin-1-yl) 
45  Me  NH2  o-Ac  5'-(4-methyl-piperazin-1-yl) 
46  Me  NH2  o-OMe  4'-(4-methyl-piperazin-1-yl) 
47  Me  NH2  o-OMe  5'-(4-methyl-piperazin-1-yl) 
3.2. Molecular Modeling and Alignment  
Molecular modeling and statistical analysis were performed using the molecular modeling package 
SYBYL 8.1 Tripos, Inc. [16]. The three-dimensional structures of all compounds were constructed 
using the Sketch Molecule module. Energy minimization of each structure was performed using the 
SYBYL  energy  minimizer  Tripos  force  field  and  Gasteiger-Hü ckel  charge  [17,18].  All  of  the 
compounds were aligned into a lattice box by fitting with common substructure (Figure 12) using 
compound 19 as a template, which was one of the most active compounds. The conformation of the 
template  was  based  on  crystallographic  ligand/receptor  complex.  (The  aligned  molecules  in  the 
training set are shown in Figure 13). 
Figure 12. Common substructure used for alignment. 
N
N
N N
O
N
 
Figure 13. Alignment of the compounds used in the training set. 
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3.3. CoMFA and CoMSIA Modeling 
The CoMFA descriptor fields including the steric fields and the electrostatic fields were calculated 
at each lattice with grid spacing of 1 Å and extending to 4 Å units in all three dimensions within 
defined region [17,18]. The Van Dar Waals potentials and Coulombic terms, which represented steric 
and  electrostatic  fields,  respectively,  were  calculated  by  using  the  standard  Tripos  force  field.  In 
CoMFA method, a sp
3 hybridized carbon atom with a charge of 1e was used as a probe atom, the 
energy values of the steric and electrostatic fields were truncated at 30 kcal/mol [18–20]. 
The steric, electrostatic, hydrophobic, hydrogen bond donor and hydrogen bond acceptor CoMSIA 
potential fields  were calculated  at  each lattice intersection of a regularly  spaced  grid of 1  Å and 
extending to 4 Å using a probe atom with radius 1.0 Å, +1.0 charge, and hydrophobic and hydrogen 
bond properties of +1. The attenuation factor was set to the default value of 0.3 [21]. 
3.4. Partial Least Squares (PLS) Analysis 
The partial least-squares (PLS), an extension of multiple regression analysis, was used to linearly 
correlate  the  CoMFA  and  CoMSIA  fields  to  the  pIC50  values.  The  cross-validation  analysis  was 
performed using the leave-one-out (LOO) method in which one molecule was removed from the data 
set and its activity was predicted using the model derived from the rest of the data set [20]. PLS was 
used in conjunction with the cross-validation option to determine the optimum number of components 
(ONC)  which  were  then  used  in  deriving  the  final  CoMFA  and  CoMSIA  model  without  
cross-validation.  The  ONC  was  the  number  of  components  resulted  in  highest  cross-validated 
correlated correlation coefficient  (r
2
cv) [20–22]. Column filtering was used at the default value of  
2.0  kcal/mol  in  the  cross-validation  part.  The  final  models  were  developed  with  ONC  by  using  
non-cross-validated analysis equal yielded the highest correlation coefficient (r
2) [23]. 
3.5. Predictive Correlation Co-Efficient (r
2
pred) 
The predictive abilities of 3D-QSAR models were validated by predicting the activities of a test set 
of eight compounds that were not included in the training set. These molecules were aligned to the 
template and their pIC50 values were predicted by the produced models which were obtained using the 
training set. The predictive correlation coefficient (r
2
pred), based on the molecules of test set, was 
calculated using Equation (1): 
r
2
pred = (SD − PRESS)/SD          (1) 
In this equation, SD is the sum of the squared deviations between the inhibitory activities of the test 
set  and the mean activity of  the training molecules and PRESS is  the sum  of squared deviations 
between predicted and actual activity values for each molecule in the test set [22–26]. 
3.6. Molecular Docking 
To study the protein-ligand interactions, compound 19 with a high pIC50 value was selected as a 
reference compound and docked into the ATP-binding site of CDK2/cyclin A. The ATP binding site 
was situated in a deep cleft between a amino-terminal lobe (residues 1–85) and a carboxy-terminal Int. J. Mol. Sci. 2010, 11                       
 
 
3722 
lobe  which  contains  the  catalytic  residues  conserved  among  eukaryotic  protein  kinases.  The  ATP 
pocket  of  CDK2/cyclin  A  has  an  impressive  capacity  to  accommodate  a  variety  of  inhibitors 
containing flat heterocyclic structures [27]. The Surflex-Dock using an empirical scoring function and 
a patented search engine to dock ligands into a protein’s binding site was used to investigate molecular 
docking  [26].  The  scoring  function  was  tuned  to  predict  the  binding  affinities  of  protein/ligand 
complexes,  with  its  output  being  represented  in  units  of  −log(Kd)
2.  The  terms,  in  rough  order  of 
significance, were hydrophobic complementarity, polar complementarity, entropic terms, and solvation 
terms. The full scoring function was the sum of each of these terms [27]. 
The crystal structure of CDK2/cyclin A was obtained from Protein Data Bank, having a PDB entry 
of 2WXV. The CDK2/cyclin A structure was exploited in subsequent docking experiments without 
energy minimization. The compound 19 was docked into corresponding protein’s binding site by an 
empirical scoring function and a patented search engine in Surflex-Dock [16]. The automatic docking 
was applied. All the inhibitor and water molecules from crystal structure have been removed and the 
polar hydrogen atoms were added.  
The MOLCAD (Molecular Computer Aided Design) program was applied to visualize the binding 
mode between the ligand and protein. MOLCAD calculates and displays the surfaces of channels, 
Ribbon,  and  cavities,  as  well  as  the  separating  surface  between  protein  subunits  [16].  MOLCAD 
program provides several types to create a molecular surface, the fast Connolly method which uses a 
marching cube algorithm to generate the surface was utilized. Other parameters were established by 
default in software. 
4. Conclusion 
We have employed 3D-QSAR and docking methods to explore the structure-activity relationship of 
a series of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent CDK2/cyclin A inhibitors. 
The CoMFA  analysis was  used to  build statistically significant  models with  good correlative  and 
predictive  capability  for  the  inhibition  of  CDK2/cyclin  A  by  47  4,5-dihydro-1H-pyrazolo[4,3-h] 
quinazoline derivatives. These models could be used to predict the inhibitory potencies of related 
structures.  The  analysis  of  contours  for  the  CoMFA  models  has  provided  a  clue  about  the  
structural  requirement  for  the  observed  biological  activity  for  the  respective  kinases:  A  more  
electron-withdrawing group and less bulky substitution on the pyrazolo ring are expected to improve 
the inhibitory potency. Furthermore, the CoMSIA contour maps along with the docking results offered 
enough information that more hydrogen bond acceptor groups on the benzene ring (m,p-R3) and more 
hydrogen bond donor groups on the benzene ring (o-R3) may benefit the potency. The clues obtained 
from 3D-QSAR and docking studies can be served as a useful guideline for the amplification of the 
known  CDK2/cyclin  A  family  of  inhibitors.  The  designed  molecules  based  on  those  parameters 
showed better activity than the reference molecules, which indicates that the 3D-QSAR model that was 
generated has a good predictability and can be used to design new molecules with better activity. 
These  molecules  can  be  synthesized  to  generate  a  greater  number  of  molecules  with  required 
pharmacokinetics for further clinical studies. 
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